IL-6 promotes malignant growth of skin SCCs by regulating a network of autocrine and paracrine cytokines

International Journal of Cancer

Volumn 128, Issue 12, 2011, Pages 2803-2814

  Lederle, Wiltrud ^a,b   Depner, Sofia ^a   Schnur, Sabine ^a   Obermueller, Eva ^c   Catone, Nicola ^a   Just, Alexandra ^a   Fusenig, Norbert E ^d   Mueller, Margareta M ^a,d,e  

^a GERMAN CANCER RESEARCH CENTER   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e INF 280 ^*  (Germany)

Author keywords

cytokine network; IL 6; MMP; tumor progression

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; STAT3 PROTEIN; VASCULOTROPIN;

ARTICLE; AUTOCRINE EFFECT; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; EPITHELIUM CELL; GROWTH INHIBITION; HUMAN; HUMAN CELL; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA;

BASE SEQUENCE; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; CYTOKINES; DISEASE PROGRESSION; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IN SITU HYBRIDIZATION; INTERLEUKIN-6; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; SKIN NEOPLASMS; STAT3 TRANSCRIPTION FACTOR;

EID: 78649789584     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25621     Document Type: Article

References (51)

1. Hussain SP, Harris CC,. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 2007; 121: 2373-80. (Pubitemid 350022405)
2. de Visser KE, Coussens LM,. The inflammatory tumor microenvironment and its impact on cancer development. Contrib Microbiol 2006; 13: 118-37.
3. Lin WW, Karin M,. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007; 117: 1175-83. (Pubitemid 46718402)
4. Lewis AM, Varghese S, Xu H, Alexander HR,. Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J Transl Med 2006; 4: 48.
5. Balkwill F,. TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev 2006; 25: 409-16.
6. Yuan A, Chen JJ, Yao PL, Yang PC,. The role of interleukin-8 in cancer cells and microenvironment interaction. Front Biosci 2005; 10: 853-65.
7. Hong DS, Angelo LS, Kurzrock R,. Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer 2007; 110: 1911-28. (Pubitemid 350036849)
8. Conze D, Weiss L, Regen PS, Bhushan A, Weaver D, Johnson P, Rincon M,. Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res 2001; 61: 8851-8. (Pubitemid 34013900)
9. Trikha M, Corringham R, Klein B, Rossi JF,. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 2003; 9: 4653-65. (Pubitemid 37323267)
10. Scheller J, Rose-John S,. Interleukin-6 and its receptor: from bench to bedside. Med Microbiol Immunol 2006; 195: 173-83. (Pubitemid 44600378)
11. Kishimoto T, Akira S, Narazaki M, Taga T,. Interleukin-6 family of cytokines and gp130. Blood 1995; 86: 1243-54.
12. Yamanaka Y, Nakajima K, Fukada T, Hibi M, Hirano T,. Differentiation and growth arrest signals are generated through the cytoplasmic region of gp130 that is essential for Stat3 activation. EMBO J 1996; 15: 1557-65. (Pubitemid 26112377)
13. Gabay C,. Interleukin-6 and chronic inflammation. Arthritis Res Ther 2006; 8 (Suppl 2): S3.
14. Bachelot T, Ray-Coquard I, Menetrier-Caux C, Rastkha M, Duc A, Blay JY,. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br J Cancer 2003; 88: 1721-6. (Pubitemid 36760416)
15. Grivennikov S, Karin M,. Autocrine IL-6 signaling: a key event in tumorigenesis? Cancer Cell 2008; 13: 7-9. (Pubitemid 350309747)
16. Danforth DN, Jr, Sgagias MK,. Interleukin-1 alpha and interleukin-6 act additively to inhibit growth of MCF-7 breast cancer cells in vitro. Cancer Res 1993; 53: 1538-45. (Pubitemid 23113226)
17. Benoy I, Salgado R, Colpaert C, Weytjens R, Vermeulen PB, Dirix LY,. Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients. Clin Breast Cancer 2002; 2: 311-5. (Pubitemid 34196274)
18. Nilsson MB, Langley RR, Fidler IJ,. Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res 2005; 65: 10794-800. (Pubitemid 41713347)
19. Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ,. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 1996; 271: 736-41. (Pubitemid 26034921)
20. Lin ZQ, Kondo T, Ishida Y, Takayasu T, Mukaida N,. Essential involvement of IL-6 in the skin wound-healing process as evidenced by delayed wound healing in IL-6-deficient mice. J Leukoc Biol 2003; 73: 713-21. (Pubitemid 38040449)
21. Mueller MM, Peter W, Mappes M, Huelsen A, Steinbauer H, Boukamp P, Vaccariello M, Garlick J, Fusenig NE,. Tumor progression of skin carcinoma cells in vivo promoted by clonal selection, mutagenesis, and autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. Am J Pathol 2001; 159: 1567-79. (Pubitemid 32947984)
22. Fusenig NE, Boukamp P,. Multiple stages and genetic alterations in immortalization, malignant transformation, and tumor progression of human skin keratinocytes. Mol Carcinog 1998; 23: 144-58. (Pubitemid 28535818)
23. Obermueller E, Vosseler S, Fusenig NE, Mueller MM,. Cooperative autocrine and paracrine functions of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the progression of skin carcinoma cells. Cancer Res 2004; 64: 7801-12. (Pubitemid 39446913)
24. Stacey A, Doyle A,. Routine testing of cell cultures and their products for mycoplasma contamination. Methods Mol Biol 1997; 75: 305-11.
25. Zilberstein A, Ruggieri R, Korn JH, Revel M,. Structure and expression of cDNA and genes for human interferon-beta-2, a distinct species inducible by growth-stimulatory cytokines. EMBO J 1986; 5: 2529-37.
26. Gutschalk CM, Herold-Mende CC, Fusenig NE, Mueller MM,. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor promote malignant growth of cells from head and neck squamous cell carcinomas in vivo. Cancer Res 2006; 66: 8026-36. (Pubitemid 44299167)
27. Vosseler S, Mirancea N, Bohlen P, Mueller MM, Fusenig NE,. Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants. Cancer Res 2005; 65: 1294-305. (Pubitemid 40270156)
28. Mueller MM, Herold-Mende CC, Riede D, Lange M, Steiner HH, Fusenig NE,. Autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor in human gliomas with tumor progression. Am J Pathol 1999; 155: 1557-67.
29. Braun B, Lange M, Oeckler R, Mueller MM,. Expression of G-CSF and GM-CSF in human meningiomas correlates with increased tumor proliferation and vascularization. J Neurooncol 2004; 68: 131-40. (Pubitemid 39137337)
30. Zhong Z, Wen Z, Darnell JE, Jr., Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994; 264: 95-8. (Pubitemid 24144493)
31. Frank DA,. STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett 2007; 251: 199-210. (Pubitemid 46680370)
32. Niu G, Bowman T, Huang M, Shivers S, Reintgen D, Daud A, Chang A, Kraker A, Jove R, Yu H,. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 2002; 21: 7001-10. (Pubitemid 35252974)
33. Thaler J, Fechner F, Herold M, Huber H,. Interleukin-6 in multiple myeloma: correlation with disease activity and Ki-67 proliferation index. Leuk Lymphoma 1994; 12: 265-71. (Pubitemid 24077176)
34. Frassanito MA, Cusmai A, Iodice G, Dammacco F,. Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis. Blood 2001; 97: 483-9. (Pubitemid 32060334)
35. Lu C, Kerbel RS,. Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol 1993; 120: 1281-8. (Pubitemid 23064182)
36. Debidda M, Wang L, Zang H, Poli V, Zheng Y,. A role of STAT3 in Rho GTPase-regulated cell migration and proliferation. J Biol Chem 2005; 280: 17275-85. (Pubitemid 41389196)
37. Loeffler S, Fayard B, Weis J, Weissenberger J,. Interleukin-6 induces transcriptional activation of vascular endothelial growth factor (VEGF) in astrocytes in vivo and regulates VEGF promoter activity in glioblastoma cells via direct interaction between STAT3 and Sp1. Int J Cancer 2005; 115: 202-13. (Pubitemid 40586728)
38. Niu G, Heller R, Catlett-Falcone R, Coppola D, Jaroszeski M, Dalton W, Jove R, Yu H,. Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res 1999; 59: 5059-63. (Pubitemid 29503958)
39. Xie TX, Wei D, Liu M, Gao AC, Ali-Osman F, Sawaya R, Huang S,. Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 2004; 23: 3550-60. (Pubitemid 38658421)
40. Tsareva SA, Moriggl R, Corvinus FM, Wiederanders B, Schutz A, Kovacic B, Friedrich K,. Signal transducer and activator of transcription 3 activation promotes invasive growth of colon carcinomas through matrix metalloproteinase induction. Neoplasia 2007; 9: 279-91. (Pubitemid 46608295)
41. Fleetwood AJ, Cook AD, Hamilton JA,. Functions of granulocyte-macrophage colony-stimulating factor. Crit Rev Immunol 2005; 25: 405-28. (Pubitemid 43068934)
42. Brat DJ, Bellail AC, van Meir EG,. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro Oncol 2005; 7: 122-33. (Pubitemid 40590513)
43. Breen EC,. VEGF in biological control. J Cell Biochem 2007; 102: 1358-67. (Pubitemid 350223939)
44. Naugler WE, Karin M,. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med 2008; 14: 109-19.
45. Roca H, Varsos ZS, Sud S, Craig MJ, Ying C, Pienta KJ,. CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization. J Biol Chem 2009; 284: 34342-54.
46. Jordan RC, Macabeo-Ong M, Shiboski CH, Dekker N, Ginzinger DG, Wong DT, Schmidt BL,. Overexpression of matrix metalloproteinase-1 and -9 mRNA is associated with progression of oral dysplasia to cancer. Clin Cancer Res 2004; 10: 6460-5. (Pubitemid 39346541)
47. Tsukifuji R, Tagawa K, Hatamochi A, Shinkai H,. Expression of matrix metalloproteinase-1, -2 and -3 in squamous cell carcinoma and actinic keratosis. Br J Cancer 1999; 80: 1087-91. (Pubitemid 29233934)
48. Okamoto M, Lee C, Oyasu R,. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res 1997; 57: 141-6. (Pubitemid 27020343)
49. Ancrile B, Lim KH, Counter CM,. Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev 2007; 21: 1714-9. (Pubitemid 47076470)
50. Sasser AK, Sullivan NJ, Studebaker AW, Hendey LF, Axel AE, Hall BM,. Interleukin-6 is a potent growth factor for ER-alpha-positive human breast cancer. FASEB J 2007; 21: 3763-70. (Pubitemid 350075164)
51. Smith PC, Hobisch A, Lin DL, Culig Z, Keller ET,. Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev 2001; 12: 33-40. (Pubitemid 32294585)